Brokerages forecast that Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) will announce ($0.28) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Oramed Pharmaceuticals’ earnings, with estimates ranging from ($0.30) to ($0.25). Oramed Pharmaceuticals posted earnings per share of ($0.20) in the same quarter last year, which would suggest a negative year over year growth rate of 40%. The company is scheduled to issue its next earnings report on Wednesday, December 5th.
According to Zacks, analysts expect that Oramed Pharmaceuticals will report full year earnings of ($0.96) per share for the current financial year, with EPS estimates ranging from ($0.98) to ($0.94). For the next fiscal year, analysts forecast that the business will post earnings of ($1.14) per share, with EPS estimates ranging from ($1.24) to ($1.06). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that cover Oramed Pharmaceuticals.
Several equities analysts have commented on ORMP shares. B. Riley cut Oramed Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Monday, July 16th. ValuEngine cut Oramed Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, September 11th. Finally, HC Wainwright set a $25.00 price target on Oramed Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, October 9th.
An institutional investor recently bought a new position in Oramed Pharmaceuticals stock. BlackRock Inc. bought a new position in Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 28,041 shares of the biotechnology company’s stock, valued at approximately $209,000. BlackRock Inc. owned approximately 0.16% of Oramed Pharmaceuticals at the end of the most recent quarter. 1.52% of the stock is owned by hedge funds and other institutional investors.
Oramed Pharmaceuticals stock opened at $4.52 on Friday. The company has a market capitalization of $78.48 million, a price-to-earnings ratio of -5.72 and a beta of 0.59. Oramed Pharmaceuticals has a 12 month low of $4.07 and a 12 month high of $9.74.
Oramed Pharmaceuticals Company Profile
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes.
Further Reading: What is a bull market?
Get a free copy of the Zacks research report on Oramed Pharmaceuticals (ORMP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.